secwatch / observer
8-K filed May 6, 2026, 7:59 PM ET ticker CTOR CIK 0001851484
debt confidence high sentiment positive materiality 0.75

Citius Oncology secures up to $36.5M in debt and warrant exercise proceeds

CITIUS ONCOLOGY, INC.

item 1.01item 2.03item 3.02item 8.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001213900-26-052552
form_type
8-K
ticker
CTOR
cik
0001851484
company_name
CITIUS ONCOLOGY, INC.
filed_at
2026-05-06T23:59:59+00:00
discovered_at
2026-05-14T18:02:33.131816+00:00
generated_at
2026-05-14T22:54:20.527467+00:00
sec_items
["1.01", "2.03", "3.02", "8.01", "9.01"]
event_type
debt
sentiment
positive
materiality_score
0.75
calibrated_materiality_score
0.75
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001213900-26-052552
json_url
https://secwatch.observer/filing/0001213900-26-052552.json
markdown_url
https://secwatch.observer/filing/0001213900-26-052552.md
text_url
https://secwatch.observer/filing/0001213900-26-052552.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1851484/000121390026052552/0001213900-26-052552-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1851484/000121390026052552/ea0289297-8k_citius.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

63f1fdca1487bb37be01fb433cfb0a0faa20c21c

CITIUS ONCOLOGY, INC. entered into Warrant Inducement Agreement with the holder of certain existing warrants valued at approximately $11.5 million (effective 2026-05-05).

On May 5, 2026, Citius Oncology, Inc. (the “Company”), entered into a warrant inducement agreement (the “Warrant Inducement Agreement”) with the holder of certain existing warrants

SEC 8-K Item 1.01/1.02 confidence 0.95 SEC evidence

Comparable filings

KNX

Knight-Swift closes $1.5B convertible note offering at 1.00% due 2031; proceeds used to repay term loans and revolver

Knight-Swift Transportation Holdings Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 2.03, 3.02, 8.01, 9.01 same event type: debt similar materiality

This filing

On May 5, 2026, Citius Oncology, Inc. (the “Company”), entered into a warrant inducement agreement (the “Warrant Inducement Agreement”) with the holder of certain existing warrants

Comparable filing

On May 8, 2026, Knight-Swift Transportation Holdings Inc. (the "Company") completed its previously announced private offering (the "Offering") of $1.5 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2031 (the "Notes"), including the exercise in full of the initial purchasers' option to purchase up to an additional $200.0 million principal amount of the Notes.

Filing page SEC filing

PUMP

ProPetro issues $690M zero-coupon convertible notes due 2031, expands credit facility

ProPetro Holding Corp. May 7, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 2.03, 3.02, 8.01, 9.01 same event type: debt similar materiality

This filing

On May 5, 2026, Citius Oncology, Inc. (the “Company”), entered into a warrant inducement agreement (the “Warrant Inducement Agreement”) with the holder of certain existing warrants

Comparable filing

On May 7, 2026, ProPetro Holding Corp. (the “ Company ”), issued $690 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2031 (the “ Notes ”), which included the exercise in full of the Initial Purchasers’ (as defined below) option to purchase up to an additional $90 million principal amount of Notes. The Notes were issued pursuant to, and are governed by, an indenture (the “ Indenture ”), dated as of May 7, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “ Trustee ”).

Filing page SEC filing

EMAT

EMAT secures $100M convertible debenture facility from Yorkville; first $20M tranche issued

Evolution Metals & Technologies Corp. May 11, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 7.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On May 5, 2026, Citius Oncology, Inc. (the “Company”), entered into a warrant inducement agreement (the “Warrant Inducement Agreement”) with the holder of certain existing warrants

Comparable filing

On May 7, 2026, Evolution Metals & Technologies Corp. (“EMAT” or the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with YA II PN, LTD. (“Yorkville”), a fund managed by Yorkville Advisors Global, LP, pursuant to which the Company agreed to issue and sell to Yorkville convertible debentures in the aggregate principal amount of up to $100,000,000

Filing page SEC filing

TBH

Brag House issues $2.5M convertible notes at 25% OID; proceeds for House of Doge merger

Brag House Holdings, Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On May 5, 2026, Citius Oncology, Inc. (the “Company”), entered into a warrant inducement agreement (the “Warrant Inducement Agreement”) with the holder of certain existing warrants

Comparable filing

In connection with the Offering, on May 4, 2026, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Purchasers.

Filing page SEC filing

OCGN

Ocugen completes $115M convertible note offering at 6.75%, repays Avenue loan

Ocugen, Inc. May 7, 2026, 7:59 PM ET debt Items 1.01, 1.02, 2.02, 2.03, 3.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On May 5, 2026, Citius Oncology, Inc. (the “Company”), entered into a warrant inducement agreement (the “Warrant Inducement Agreement”) with the holder of certain existing warrants

Comparable filing

On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”). The notes were issued pursuant to an indenture, dated May 7, 2026 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee.

Filing page SEC filing

LIQT

LiqTech to convert $3M of $6M debt to equity, pay $3M cash in restructuring

LIQTECH INTERNATIONAL INC June 1, 2026, 5:17 PM ET debt Items 1.01, 3.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 9.01 same event type: debt similar materiality

This filing

On May 5, 2026, Citius Oncology, Inc. (the “Company”), entered into a warrant inducement agreement (the “Warrant Inducement Agreement”) with the holder of certain existing warrants

Comparable filing

On May 26, 2026, LiqTech International, Inc. (the “Company”) entered into a Debt Cancellation Agreement (the “Debt Cancellation Agreement”) with affiliates of Bleichroeder L.P., 21 April Fund, L.P., and 21 April Fund, Ltd. (the “Note Holders”).

Filing page SEC filing

TSEOF

Trinseo obtains $142.5M new money DIP financing and $150M AR facility in Chapter 11

Trinseo PLC June 1, 2026, 4:23 PM ET debt Items 1.01, 2.03, 9.01

same fact type: material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On May 5, 2026, Citius Oncology, Inc. (the “Company”), entered into a warrant inducement agreement (the “Warrant Inducement Agreement”) with the holder of certain existing warrants

Comparable filing

On May 28, 2026, the Company, as parent, Trinseo NA Finance LLC, as holdings, Trinseo Luxco Finance SPV S.à r.l. and Trinseo NA Finance SPV LLC (together, the “ SHC Borrowers ”), as borrowers, the guarantors party thereto from time to time, the lenders party thereto from time to time (the “ SHC DIP Lenders ”), and Alter Domus (US) LLC, as administrative agent and collateral agent, entered into a Senior Secured Super-Priority Debtor-In-Possession HoldCo Credit Agreement (the “ Super-Holdco DIP Credit Agreement ”), providing for a senior secured super-priority priming term loan debtor-in-possession credit facility in an aggregate principal amount of $157.5 million (the “ Super-Holdco DIP Facility ”).

Filing page SEC filing

VVX

V2X refinances $868.5M term loans with new tranche maturing 2030; SOFR+2% margin

V2X, Inc. June 1, 2026, 4:10 PM ET debt Items 1.01, 2.03, 9.01

same fact type: material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On May 5, 2026, Citius Oncology, Inc. (the “Company”), entered into a warrant inducement agreement (the “Warrant Inducement Agreement”) with the holder of certain existing warrants

Comparable filing

entered into Amendment No. 6 to First Lien Credit Agreement, dated as of May 29, 2026 (the “Amendment”), with Royal Bank of Canada, as administrative agent and collateral agent, and the other financial institutions and lenders party thereto

Filing page SEC filing

Source: SEC EDGAR
accession 0001213900-26-052552
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.